Hypogonadism: Expert panel adopts nine resolutions
An international group of physician and scientific experts, including several urologists, recently approved nine resolutions that offer physicians and patients what they say is evidence-based clarity on the topic of male hypogonadism and its management.
"The medical and scientific communities are still largely unaware of the major negative impact of testosterone deficiency on general health. The media-driven focus on unproven risks has obscured the known health risks of untreated testosterone deficiency: obesity, reduced bone mineral density, and increased mortality,” panel member Abdulmaged Traish, MBA, PhD, of Boston University Medical Center, Boston said in a press release.
The nine resolutions, published in Mayo Clinic Proceedings (2016; 91:881-96), begin with defining testosterone deficiency (TD) as a “well-established, clinically significant medical condition that negatively affects male sexuality, reproduction, general health and quality of life.” The others include:
- Symptoms and signs of TD occur as a result of low levels of testosterone and may benefit from treatment regardless of whether there is an identified underlying origin.
- There is no scientific basis for any age-specific recommendations against the use of testosterone therapy in adult males.
- The evidence does not support increased risks of cardiovascular events or prostate cancer with testosterone therapy.
- The evidence supports a major research initiative to explore possible benefits of testosterone therapy for cardiometabolic disease, including diabetes.